期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 20, 期 4, 页码 519-535出版社
INFORMA HEALTHCARE
DOI: 10.1517/13543784.2011.565330
关键词
antidepressants; corticotropin releasing factor antagonists; hypothalamus-pituitary-adrenal axis; major depression; personalized medicine; stress
资金
- Max Planck Institute of Psychiatry
Areas covered: The use of corticotropin releasing factor type 1 (CRF1) receptor antagonists for depression is supported by abundant evidence of target validation, the availability of in vitro and in vivo assays and specific small ligands. Some of these compounds have advanced to clinical studies, with discouraging results so far in depression. This review covers the development of CRF1 receptor antagonists at different stages of the development pipeline of the pharmaceutical industry and its bottlenecks. Most of the available CRF1 receptor antagonists known so far share a common chemical scaffold. We present possible strategies to overcome obstacles in the discovery and development process at the levels of library screenings and clinical studies to find more diverse compounds. Expert opinion: CRF1 receptor antagonists are expected to be beneficial only for those patients with CRF overexpression and the need for tests to identify these individuals is discussed. New technical developments and diagnostic tools might eventually lead to a more successful treatment of major depression with CRF1 receptor antagonists.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据